Tempest Therapeutics
TPST
35 hedge funds and large institutions have $5.89M invested in Tempest Therapeutics in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
20% more capital inflows, than outflows
Capital inflows: $2.7M | Capital outflows: $2.25M
6% more funds holding
Funds holding: 33 → 35 (+2)
1.97% more ownership
Funds ownership: 20.6% → 22.57% (+2%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$1.26M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$933K |
| 3 |
AIC
AWM Investment Company
New York
|
+$248K |
| 4 |
Renaissance Technologies
New York
|
+$123K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$86.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.16M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$574K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
-$207K |
| 4 |
D.E. Shaw & Co
New York
|
-$112K |
| 5 |
Employees Retirement System of Texas
Austin,
Texas
|
-$81K |
TPST Hedge Fund Activity: Q3 2018 in Review
35 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2018, worth a combined $5.89M — down 12% from $6.68M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TPST positions and 8 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $1.26M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $1.16M sold.
- 35 institutional investors held Tempest Therapeutics (TPST) as of Q3 2018, up from 33 in Q2 2018.
- Funds reported $5.89M of Tempest Therapeutics stock for Q3 2018, down 12% quarter-over-quarter.
- 10 funds opened new Tempest Therapeutics positions in Q3 2018 and 8 closed out, a net change of +2 holders.
- The largest Tempest Therapeutics buyer in Q3 2018 was Prosight Management, an estimated $1.26M added.
- The largest Tempest Therapeutics seller in Q3 2018 was Adage Capital Partners, an estimated $1.16M sold.
Based on aggregated 13F filings for Q3 2018.